Delivery Order SPE2DB22D9244-SPE2DB24FZS62

Award Date 8/26/24
Potential Completion Date 9/17/24
Potential Value $36K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is for the delivery of NEXPLANON 68 MG IMPLANTS to the Defense Logistics Agency (DLA), a defense agency within the U.S. Department of Defense (DoD). The contract, valued at $5,717.52, was awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is a firm fixed-price delivery order with no set-aside designation, and it has an ultimate completion date of September 9, 2024. DMS...
This federal contract award is for the delivery of NEXPLANON 68 MG IMPLANTS to the Defense Logistics Agency (DLA), a defense agency under the U.S. Department of Defense. The $8,576.28 firm fixed-price contract was awarded on July 17, 2024 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract has an ultimate completion date of August 7, 2024 and is not designated as a set-aside. DMS Pharmaceutical Group Inc. holds a...
This federal contract award is for the delivery of NEXPLANON 68 MG IMPLANTS to the Defense Logistics Agency (DLA), a defense agency under the U.S. Department of Defense (DoD). The $3,573.45 firm fixed-price delivery order was awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. DMS Pharmaceutical Group Inc. holds a significant indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to...
The federal contract award is for the delivery of NEXPLANON 68 MG IMPLANTS to the Defense Logistics Agency (DLA), a defense agency under the U.S. Department of Defense. The contract was awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is a firm fixed-price delivery order with a ceiling value of $8,576.28 and an ultimate completion date of October 17, 2024. DMS Pharmaceutical Group Inc. holds a significant...
The federal contract award is for the purchase of NEXPLANON 68 MG IMPLANTS by the Defense Logistics Agency (DLA), a defense agency. The contract was awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The firm fixed-price Delivery Order contract is valued at $7,146.90 and has a completion date of May 16, 2024. This award is part of a larger $499,999,999 indefinite delivery contract (IDC) held by DMS Pharmaceutical...
This federal contract award is for the delivery of NEXPLANON 68 MG IMPLANTS to the Defense Logistics Agency (DLA), a defense agency under the Department of Defense (DoD). The contract, valued at $2,734.96, was awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is a firm fixed-price delivery order issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract (IDC) with the DLA, valued at up...
This federal contract award is for the delivery of NEXPLANON 68 MG IMPLANTS to the Defense Logistics Agency (DLA), a defense agency under the U.S. Department of Defense (DoD). The contract, valued at $4,288.14, is a firm fixed-price delivery order awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is part of a larger $499,999,999 indefinite delivery contract (IDC) that DMS Pharmaceutical Group holds with...
This federal contract award is for NEXPLANON 68 MG IMPLANTS, a pharmaceutical product, with a ceiling value of $7,146.90. The contract was awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The award was issued by the Defense Logistics Agency (DLA), specifically the Medical Supply Chain division, which is part of the Department of Defense (DoD). DMS Pharmaceutical Group Inc. holds a significant indefinite delivery...
This federal contract award is for the delivery of NEXPLANON 68 MG IMPLANTS to the Defense Logistics Agency (DLA), a defense agency under the Department of Defense (DoD). The contract was awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $13,886.20 firm fixed-price delivery order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB...
This federal contract award is for the delivery of NEXPLANON 68 MG IMPLANTS to the Defense Logistics Agency (DLA), a defense agency. The contract, valued at $7,146.90, is a firm-fixed price delivery order with no set-aside designation. It was awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. DMS Pharmaceutical Group holds a larger indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to...
  • SPE2DB22D9244
    Indefinite Delivery Contract
  • SPE2DB22D9244-SPE2DB24FZS62
    Delivery Order

This federal contract award is for the supply of NEXPLANON 68 MG IMPLANTS to the Defense Logistics Agency (DLA), a defense agency under the U.S. Department of Defense (DoD). The contract was awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. This is a firm fixed-price delivery order contract with a ceiling value of $35,734.50 and a performance period ending on September 17, 2024.

The contract is not set-aside and represents a direct award to DMS Pharmaceutical Group under the agency's SPE2DB pharmaceutical supply program. DMS Pharmaceutical Group holds a larger indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to $499,999,999, which allows the DLA to issue delivery orders for a wide range of pharmaceutical products to support the medical needs of military healthcare facilities worldwide. This contract for NEXPLANON implants is one such delivery order issued against the overarching SPE2DB IDC.

Generated 11/25/24, 9:24 AM